Investigational drug · Phase 3
QLC7401
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Hypercholesterolemia or Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "QLC7401"
First trial start
2025
Feb 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLC7401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Heterozygous Familial Hypercholesterolemia (HeFH)
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "QLC7401" as an intervention, largest first.
- QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07441317 · 780 participants (planned) · Start Mar 2026 · Primary completion Dec 2027
Drug: QLC7401; Placebo · For: Primary Hypercholesterolemia or Mixed Hyperlipidemia
- QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed DyslipidemiaPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07444086 · 510 participants (planned) · Start Mar 5, 2026 · Primary completion Oct 7, 2027
Drug: QLC7401; Placebo · For: Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL CholesterolPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06750341 · 156 participants (planned) · Start Feb 2025 · Primary completion Jun 2026
Drug: QLC7401; Placebo · For: Primary Hypercholesterolemia or Mixed Hyperlipidemia
- QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07450378 · 120 participants (planned) · Start May 2026 · Primary completion Apr 2028
Drug: QLC7401 Injection; Placebo · For: Heterozygous Familial Hypercholesterolemia (HeFH)
- Pharmacokinetics and Pharmacodynamics StudyNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07074236 · 48 participants (planned) · Start Jul 2025 · Primary completion Jan 2026
Drug: QLC7401 injection; RBD7022 injection · For: Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.